SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated January 9, 2004
(Commission File No. 1-15024)
-----------------
Novartis AG
(Name of Registrant)
-----------------
Lichtstrasse 35
4056 Basel
Switzerland
-----------------
(Address of Principal Executive Offices)
-----------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F: |X| Form 40-F: |_|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes: |_| No: |X|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes: |_| No: |X|
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: |_| No: |X|
Enclosure: Invitation to Participate in Novartis' Full Year Results 2003
Presentation.
Investor Relations Novartis International AG
CH-4002 Basel
Switzerland
[GRAPHIC OMITTED] Novartis Corporation
608 Fifth Avenue
New York, NY 10020
USA
--------------------------------
-SAVE THE DATE-
--------------------------------
Novartis' Full Year Results 2003 Presentation
to be held
in Zurich, Switzerland
on
Thursday, January 22, 2004
Door opening at 13.30, start at 14:00
# # #
-------------------------------------------------------- ----------------------------------------------
Novartis Global Investor Relations
-------------------------------------------------------- ----------------------------------------------
Karen J. Huebscher, Ph.D. +41 61 324 84 33
-------------------------------------------------------- ----------------------------------------------
International office North American office
Nafida Bendali +41 61 324 35 14 Alex Kelly +1 212 830 24 45
Katharina Furrer +41 61 324 53 16 John Menditto +1 212 830 24 44
Silke Zentner +41 61 324 86 12 Sabine Moravi +1 212 830 24 56
Jill Pozarek +1 212 830 24 45
e-mail: investor.relations@group.novartis.com e-mail: investor.relations@group.novartis.com
Fax: +41 61 324 84 44 Fax: +1 212 830 24 05
www.novartis.com www.novartis.com
-------------------------------------------------------- ----------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
Novartis AG has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NOVARTIS AG
Date: January 9, 2004 By: /s/ MALCOLM CHEETHAM
-----------------------------
Name: Malcolm Cheetham
Title: Head Group Financial Reporting
and Accounting